XTL licenses development rights to pain therapy

XTL Biopharmaceuticals has agreed to pay $7.5 million upfront and up to $126.5 million in cash and shares to DOV Pharmaceutical to license development rights to bicifadine as a treatment for neuropathic pain. Bicifadine has been evaluated in 15 clinical trials, including two trials in patients suffering from acute (non-neuropathic) pain, where Bicifadine demonstrated statistically significant efficacy.

- see the release on the licensing pact

Related Articles
DOV formulates new development strategy. Report
DOV CEO resigns in shakeup. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.